18F-FLT and 18F-FDG PET-CT imaging in the evaluation of early therapeutic effects of chemotherapy on Walker 256 tumor-bearing rats

Xu,Weina; Yu,Shupeng; Xin,Jun; Guo,Qiyong

doi:10.3892/etm.2016.3869

18F-FLT and 18F-FDG PET-CT imaging in the evaluation of early therapeutic effects of chemotherapy on Walker 256 tumor-bearing rats

Authors:
- Weina Xu
- Shupeng Yu
- Jun Xin
- Qiyong Guo
View Affiliations

Affiliations: Department of Nuclear Medicine, Shengjing Hospital, China Medical University, Shenyang 110004, P.R. China, Department of Radiology, Shengjing Hospital, China Medical University, Shenyang 110004, P.R. China
Published online on: November 3, 2016 https://doi.org/10.3892/etm.2016.3869
Pages: 4154-4158

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the early therapeutic effects of chemotherapy on Walker 256 tumor-bearing Wistar rats via F-18-fluoro-3'-deoxy-3'-L-fluorothymidine (18F-FLT) and F-18-fluoro-deoxyglucose (18F-FDG) positron emission tomography‑computed tomography (PET‑CT) imaging. Walker 256 tumor‑bearing Wistar rats were subjected to 18F‑FLT and 18F‑FDG PET‑CT imaging prior to and 24 and 48 h after epirubicin chemotherapy. 18F‑FLT and 18F‑FDG uptake [tumor/muscle (T/M)], the percentage of injected dose per gram (% ID/g), and the Ki‑67 labeling index (LI‑Ki‑67) were quantitatively determined for each rat prior to and following epirubicin chemotherapy. The correlation between % ID/g and tumor LI‑Ki‑67 was analyzed. Both 18F‑FLT and 18F‑FDG tumor uptake decreased significantly at 24 and 48 h after chemotherapy (P<0.01 and P<0.05, respectively). LI‑Ki‑67 also significantly reduced 24 and 48 h after chemotherapy (P<0.001). Furthermore, 18F‑FLT and 18F‑FDG T/M tumor uptake correlated positively with LI‑Ki‑67 before and after chemotherapy (r=0.842 and 0.813, respectively). During the early post‑chemotherapy stage, 18F‑FLT and 18F‑FDG uptake in Walker 256 tumors reduced significantly, which correlated positively with the tumor cell proliferative activity.

View Figures

View References

1	Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D and Piccart MJ: Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann Oncol. 16:1723–1739. 2005. View Article : Google Scholar : PubMed/NCBI
2	Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, Yanagihara K, Li M, Tanaka F, Wada H, et al: [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 7:369–379. 2005. View Article : Google Scholar : PubMed/NCBI
3	Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O and Mangner TJ: Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 4:1334–1336. 1998. View Article : Google Scholar : PubMed/NCBI
4	Grierson JR and Shields AF: Radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine: [18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 27:143–156. 2000. View Article : Google Scholar : PubMed/NCBI
5	Rasey JS, Grierson JR, Wiens LW, Kolb PD and Schwartz JL: Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 438:1210–1217. 2002.
6	Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN and Hetzel M: Imaging proliferation in lung tumours with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 44:1426–1431. 2003.PubMed/NCBI
7	Mier W, Haberkorn U and Eisenhut M: [18F]FLT; portrait of a proliferation marker. Eur J Nucl Med Mol Imaging. 29:165–169. 2002. View Article : Google Scholar : PubMed/NCBI
8	Shields AF: Positron emission tomography measurement of tumour metabolism and growth: Its expanding role in oncology. Mol Imaging Biol. 8:141–150. 2006. View Article : Google Scholar : PubMed/NCBI
9	McKinley ET, Smith RA, Zhao P, Fu A, Saleh SA, Uddin MI, Washington MK, Coffey RJ and Manning HC: 3′-Deoxy-3′-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med. 54:424–430. 2013. View Article : Google Scholar : PubMed/NCBI
10	Mason NS, Lopresti BJ, Ruszkiewicz J, Dong X, Joyce S, Leef G, Sen M, Wahed AS, Mathis CA, Grandis JR and Thomas SM: Utility of 3′-[(18)F]fluoro-3′-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. Am J Nucl Med Mol Imaging. 3:16–31. 2013.PubMed/NCBI
11	Hoeben BA, Troost EG, Span PN, van Herpen CM, Bussink J, Oyen WJ and Kaanders JH: 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med. 54:532–540. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wang H, Liu B, Tian J, Xu B, Zhang J, Qu B and Chen Y: Evaluation of ¹⁸F-FDG and ¹⁸F-FLT for monitoring therapeutic responses of colorectal cancer cells to radiotherapy. Eur J Radiol. 82:e484–e491. 2013. View Article : Google Scholar : PubMed/NCBI
13	Li Z, Herrmann K, Pirsig S, Philipp-Abbrederis K, Henninger M, Aichler M, Feuchtinger A, Walch A, Beer AJ, Ringshausen I, et al: Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma. Am J Nucl Med Mol Imaging. 4:70–79. 2013.PubMed/NCBI
14	Geven EJ, Evers S, Nayak TK, Bergström M, Su F, Gerrits D, Franssen GM and Boerman OC: Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: Evaluation of (18) F-FDG-PET and (18) F-FLT-PET. Contrast Media Mol Imaging. 10:203–210. 2015. View Article : Google Scholar : PubMed/NCBI
15	Keen HG, Ricketts SA, Maynard J, Logie A, Odedra R, Shannon AM, Wedge SR and Guichard SM: Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055. Mol Imaging Biol. 16:421–430. 2014. View Article : Google Scholar : PubMed/NCBI
16	Krohn KA, Mankoff DA, Muzi M, Link JM and Spence AM: Ture tracers: Compraring FDG with glucose and FLT with thymidine. Nucl Med Biol. 32:663–671. 2005. View Article : Google Scholar : PubMed/NCBI
17	Grasl-Kraupp B, Ruttkay-Nedecky B, Müllauer L, Taper H, Huber W, Bursch W and Schulte-Hermann R: Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology. 25:906–912. 1997. View Article : Google Scholar : PubMed/NCBI
18	Kolaja KL, Stevenson DE, Walborg EF Jr and Klaunig JE: Reversibility of promoter induced hepatic focal lesion growth in mice. Carcinogenesis. 17:1403–1407. 1996. View Article : Google Scholar : PubMed/NCBI
19	Monteiro LJ, Khongkow P, Kongsema M, Morris JR, Man C, Weekes D, Koo CY, Gomes AR, Pinto PH, Varghese V, et al: The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene. 32:4634–4645. 2013. View Article : Google Scholar : PubMed/NCBI
20	Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ and Elsinga PH: [18F]FLT-PET in oncology: Current status and opportunities. Eur J Nucl Med Mol Imaging. 31:1659–1672. 2004. View Article : Google Scholar : PubMed/NCBI
21	Munch-Petersen B, Cloos L, Jensen HK and Tyrsted G: Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul. 35:69–89. 1995. View Article : Google Scholar : PubMed/NCBI
22	Boothman DA, Davis TW and Sahijdak WM: Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int J Radiat Oncol Biol Phys. 30:391–398. 1994. View Article : Google Scholar : PubMed/NCBI
23	Kauffman MG and Kelly TJ: Cell cycle regulation of thymidine kinase: Residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol. 11:2538–2546. 1991. View Article : Google Scholar : PubMed/NCBI
24	Cole PD, Smith AK and Kamen BA: Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother Pharmacol. 50:111–116. 2002. View Article : Google Scholar : PubMed/NCBI
25	Foekens JA, Romain S, Look MP, Martin PM and Klijn JG: Thymidine kinase and thymidylate synthase in advanced breast cancer: Response to tamoxifen and chemotherapy. Cancer Res. 61:1421–1425. 2001.PubMed/NCBI
26	Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M and Bares R: Early changes in [18F]FLT uptake after chemotherapy: An experimental study. Eur J Nucl Med Mol Imaging. 29:1462–1469. 2002. View Article : Google Scholar : PubMed/NCBI
27	Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, Wehrmann M, Machulla HJ and Bares R: [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging. 30:1407–1412. 2003. View Article : Google Scholar : PubMed/NCBI